Proteome-Based Plasma Biomarkers for Cognitive Dysfunction in an Androgen Deprivation Model
- PMID: 41315084
- DOI: 10.1007/s12035-025-05548-3
Proteome-Based Plasma Biomarkers for Cognitive Dysfunction in an Androgen Deprivation Model
Abstract
Cognitive dysfunction frequently arises from androgen deprivation therapy (ADT), a primary treatment for men with prostate cancer. ADT affects key cognitive functions like memory, learning, reasoning, and decision-making. Extant studies lack a systematic evaluation of biomarkers related to ADT's cognitive impact. To address this, we used nano-liquid chromatography tandem mass spectrometry (nLC-MS/MS) to identify biomarkers in specific brain regions of a mouse model. Sixteen-week-old BALB/c mice received enzalutamide, a nonsteroidal antiandrogen, at 50 mg/kg/day via oral gavage 5 days a week for 8 weeks to simulate the ADT protocol. Control mice received a comparable volume of the vehicle. Enzalutamide treatment resulted in modest weight gain along with behavioral changes, including attention deficits and reduced social activity. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) showed altered glucose metabolism in the brain and peripheral tissues of treated mice. Histological analysis of brain sections revealed preserved neuron structure in control mice, whereas enzalutamide-treated mice showed decreased neuron density, signs of neuron damage, and astrocyte swelling. Proteomic analysis of the cortex, cerebellum, and hippocampus after euthanasia identified 29 proteins with altered expression linked to cognitive dysfunction in ADT-treated mice. Further validation showed significantly increased levels of Pum2, Mcur1, Slc39a14, Fbxo7, Myo10, Arl6ip1, Slc8a3, Mt1, and Mt3 in the blood plasma of treated mice compared to controls. These results suggest that blood could be a valuable source of biomarkers for ADT-induced cognitive dysfunction. Further studies are needed to assess their clinical applicability in monitoring cognitive decline in prostate cancer patients on ADT and in neurotypical aging.
Keywords: Androgen deprivation therapy; Androgen receptor; Cognitive dysfunction; Enzalutamide; Proteomics.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests.
References
-
- Wu LM, Diefenbach MA, Gordon WA, Cantor JB, Cherrier MM (2013) Cognitive problems in patients on androgen deprivation therapy: a qualitative pilot study. Urol Oncol 31(8):1533–1538. https://doi.org/10.1016/j.urolonc.2012.07.003 - DOI - PubMed
-
- Zhang C, Aida M, Saggu S, Yu H, Zhou L, Rehman H, Jiao K, Liu R et al (2024) Androgen deprivation therapy exacerbates Alzheimer’s-associated cognitive decline via increased brain immune cell infiltration. Sci Adv 10(25):eadn8709. https://doi.org/10.1126/sciadv.adn8709 - DOI - PubMed - PMC
-
- Reiss AB, Gulkarov S, Pinkhasov A, Sheehan KM, Srivastava A, De Leon J, Katz AE (2023) Androgen deprivation therapy for prostate cancer: focus on cognitive function and mood. Medicina 60(1):77. https://doi.org/10.3390/medicina60010077 - DOI - PubMed - PMC
-
- Shim M, Bang WJ, Oh CY, Lee YS, Cho JS (2022) Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link? Prostate Int 10(1):68–74. https://doi.org/10.1016/j.prnil.2021.02.002 - DOI - PubMed
-
- Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787–790. https://doi.org/10.1126/science.1168175 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
